APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Growth and Trends Forecast to 2032

22 December 2025112 pages

Choose your research edition.

Industry ResearchLyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection include China Biologic Products, Inc., Takeda Pharmaceutical, Shenzhen Weiguang Biological Products, Taibang Biologic Group, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Shanghai RAAS, Pacific Shuanglin Bio-pharmacy, Nanjing Pharmacare Co.,Ltd and Grifols, S.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Company

China Biologic Products, Inc.

Takeda Pharmaceutical

Shenzhen Weiguang Biological Products

Taibang Biologic Group

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Shanghai RAAS

Pacific Shuanglin Bio-pharmacy

Nanjing Pharmacare Co.,Ltd

Grifols, S.A.

Hualan Biological Engineering Inc.

Harbin Pacific Biopharmaceutical

Sinopharm Group Co., Ltd.

Boya Bio-Pharmaceutical Group Co., Ltd.

Bayer AG

Baxter International Inc.

Octapharma AG

CSL Behring

ADMA Biologics, Inc.

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Type

5g

2.5g

1.25g

Others

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Application

Hospitals

Clinics

Others

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 5g Table 2. Major Company of 2.5g Table 3. Major Company of 1.25g Table 4. Major Company of Others Table 5. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (k units) Table 7. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type (2021-2026) Table 8. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (US$ Million) Table 9. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type (2021-2026) Table 10. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Type (2021-2026) & (US$/unit) Table 11. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2027-2032) & (k units) Table 12. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type (2027-2032) Table 13. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2027-2032) & (US$ Million) Table 14. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type (2027-2032) Table 15. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Type (2027-2032) & (US$/unit) Table 16. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (k units) Table 17. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (k units) Table 19. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (k units) Table 23. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2021-2026) & (US$ Million) Table 26. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Trends Table 27. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Drivers Table 28. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Opportunities and Challenges Table 29. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Restraints Table 30. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company (2021-2026) Table 32. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Company (2021-2026) & (k units) Table 33. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Share by Company (2021-2026) Table 34. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Major Company Production Sites and Headquarters Table 37. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Company, Product Type & Application Table 38. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026) & (k units) Table 43. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Region (2021-2026) Table 44. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026) & (US$ Million) Table 45. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Region (2021-2026) Table 46. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2027-2032) & (k units) Table 48. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Region (2027-2032) Table 49. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2027-2032) & (US$ Million) Table 50. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Region (2027-2032) Table 51. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (k units) Table 54. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application (2021-2026) Table 55. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (US$ Million) Table 56. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application (2021-2026) Table 57. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Application (2021-2026) & (US$/unit) Table 58. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2027-2032) & (k units) Table 59. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application (2027-2032) Table 60. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2027-2032) & (US$ Million) Table 61. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application (2027-2032) Table 62. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Application (2027-2032) & (US$/unit) Table 63. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (k units) Table 64. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (k units) Table 66. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (k units) Table 70. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (US$ Million) Table 73. China Biologic Products, Inc. Company Information Table 74. China Biologic Products, Inc. Business Overview Table 75. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 77. China Biologic Products, Inc. Recent Development Table 78. Takeda Pharmaceutical Company Information Table 79. Takeda Pharmaceutical Business Overview Table 80. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 82. Takeda Pharmaceutical Recent Development Table 83. Shenzhen Weiguang Biological Products Company Information Table 84. Shenzhen Weiguang Biological Products Business Overview Table 85. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 87. Shenzhen Weiguang Biological Products Recent Development Table 88. Taibang Biologic Group Company Information Table 89. Taibang Biologic Group Business Overview Table 90. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 92. Taibang Biologic Group Recent Development Table 93. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information Table 94. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Business Overview Table 95. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 97. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Development Table 98. Shanghai RAAS Company Information Table 99. Shanghai RAAS Business Overview Table 100. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 102. Shanghai RAAS Recent Development Table 103. Pacific Shuanglin Bio-pharmacy Company Information Table 104. Pacific Shuanglin Bio-pharmacy Business Overview Table 105. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 107. Pacific Shuanglin Bio-pharmacy Recent Development Table 108. Nanjing Pharmacare Co.,Ltd Company Information Table 109. Nanjing Pharmacare Co.,Ltd Business Overview Table 110. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 112. Nanjing Pharmacare Co.,Ltd Recent Development Table 113. Grifols, S.A. Company Information Table 114. Grifols, S.A. Business Overview Table 115. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 117. Grifols, S.A. Recent Development Table 118. Hualan Biological Engineering Inc. Company Information Table 119. Hualan Biological Engineering Inc. Business Overview Table 120. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 122. Hualan Biological Engineering Inc. Recent Development Table 123. Harbin Pacific Biopharmaceutical Company Information Table 124. Harbin Pacific Biopharmaceutical Business Overview Table 125. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 127. Harbin Pacific Biopharmaceutical Recent Development Table 128. Sinopharm Group Co., Ltd. Company Information Table 129. Sinopharm Group Co., Ltd. Business Overview Table 130. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 132. Sinopharm Group Co., Ltd. Recent Development Table 133. Boya Bio-Pharmaceutical Group Co., Ltd. Company Information Table 134. Boya Bio-Pharmaceutical Group Co., Ltd. Business Overview Table 135. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 137. Boya Bio-Pharmaceutical Group Co., Ltd. Recent Development Table 138. Bayer AG Company Information Table 139. Bayer AG Business Overview Table 140. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 142. Bayer AG Recent Development Table 143. Baxter International Inc. Company Information Table 144. Baxter International Inc. Business Overview Table 145. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 147. Baxter International Inc. Recent Development Table 148. Octapharma AG Company Information Table 149. Octapharma AG Business Overview Table 150. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 151. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 152. Octapharma AG Recent Development Table 153. CSL Behring Company Information Table 154. CSL Behring Business Overview Table 155. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 156. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 157. CSL Behring Recent Development Table 158. ADMA Biologics, Inc. Company Information Table 159. ADMA Biologics, Inc. Business Overview Table 160. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 161. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio Table 162. ADMA Biologics, Inc. Recent Development Table 163. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 164. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 165. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026) Table 166. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (k units) Table 167. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Country (2027-2032) Table 168. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026) & (US$ Million) Table 170. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country (2021-2026) Table 171. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share Forecast by Country (2027-2032) Table 173. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 174. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 175. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026) Table 176. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (k units) Table 177. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Country (2027-2032) Table 178. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026) & (US$ Million) Table 180. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country (2021-2026) Table 181. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share Forecast by Country (2027-2032) Table 183. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 184. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 185. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026) Table 186. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (k units) Table 187. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Country (2027-2032) Table 188. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026) & (US$ Million) Table 190. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country (2021-2026) Table 191. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share Forecast by Country (2027-2032) Table 193. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 194. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 195. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026) Table 196. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (k units) Table 197. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Country (2027-2032) Table 198. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026) & (US$ Million) Table 200. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country (2021-2026) Table 201. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share Forecast by Country (2027-2032) Table 203. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 204. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (k units) Table 205. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026) Table 206. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (k units) Table 207. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Country (2027-2032) Table 208. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 209. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026) & (US$ Million) Table 210. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country (2021-2026) Table 211. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 212. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share Forecast by Country (2027-2032) Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors List Table 216. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Image Figure 2. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (2021-2032) & (k units) Figure 5. 5g Image Figure 6. Global 5g Sales YoY Growth (2021-2032) & (k units) Figure 7. 2.5g Image Figure 8. Global 2.5g Sales YoY Growth (2021-2032) & (k units) Figure 9. 1.25g Image Figure 10. Global 1.25g Sales YoY Growth (2021-2032) & (k units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Type 2025 VS 2032 Figure 15. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2025 Figure 16. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2025 Figure 17. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2025 Figure 18. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2025 Figure 21. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospitals Image Figure 28. Global Hospitals Sales YoY Growth (2021-2032) & (k units) Figure 29. Clinics Image Figure 30. Global Clinics Sales YoY Growth (2021-2032) & (k units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Application 2025 VS 2032 Figure 35. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2025 Figure 36. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2025 Figure 37. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2025 Figure 38. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2025 Figure 41. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2025 Figure 45. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Lyophilized Human Immunoglobulin (PH4) for

Scope & coverage.

Types
  • 5g
  • 2.5g
  • 1.25g
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • China Biologic Products, Inc.
  • Takeda Pharmaceutical
  • Shenzhen Weiguang Biological Products
  • Taibang Biologic Group
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Shanghai RAAS
  • Pacific Shuanglin Bio-pharmacy
  • Nanjing Pharmacare Co.,Ltd
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Harbin Pacific Biopharmaceutical
  • Sinopharm Group Co., Ltd.
  • Boya Bio-Pharmaceutical Group Co., Ltd.
  • Bayer AG
  • Baxter International Inc.
  • Octapharma AG
  • CSL Behring
  • ADMA Biologics, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Type
  6. 1.3.1 5g
  7. 1.3.2 2.5g
  8. 1.3.3 1.25g
  9. 1.3.4 Others
  10. 1.4 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Type
  11. 1.4.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Trends
  2. 2.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Drivers
  3. 2.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Opportunities and Challenges
  4. 2.4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2021-2026)
  2. 3.2 Global Top Players by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (2021-2026)
  3. 3.3 Global Top Players by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price (2021-2026)
  4. 3.4 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Major Company Production Sites & Headquarters
  6. 3.6 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Company, Product Type & Application
  7. 3.7 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Tier 1, Tier 2, and Tier 3
4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Regional Status and Outlook
  1. 4.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size by Region
  3. 4.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Region
  7. 4.3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Application
  1. 5.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Application
  6. 5.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 China Biologic Products, Inc.
  2. 6.1.1 China Biologic Products, Inc. Company Information
  3. 6.1.2 China Biologic Products, Inc. Business Overview
  4. 6.1.3 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  6. 6.1.5 China Biologic Products, Inc. Recent Developments
  7. 6.2 Takeda Pharmaceutical
  8. 6.2.1 Takeda Pharmaceutical Company Information
  9. 6.2.2 Takeda Pharmaceutical Business Overview
  10. 6.2.3 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  12. 6.2.5 Takeda Pharmaceutical Recent Developments
  13. 6.3 Shenzhen Weiguang Biological Products
  14. 6.3.1 Shenzhen Weiguang Biological Products Company Information
  15. 6.3.2 Shenzhen Weiguang Biological Products Business Overview
  16. 6.3.3 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  18. 6.3.5 Shenzhen Weiguang Biological Products Recent Developments
  19. 6.4 Taibang Biologic Group
  20. 6.4.1 Taibang Biologic Group Company Information
  21. 6.4.2 Taibang Biologic Group Business Overview
  22. 6.4.3 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  24. 6.4.5 Taibang Biologic Group Recent Developments
  25. 6.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  26. 6.5.1 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information
  27. 6.5.2 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Business Overview
  28. 6.5.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  30. 6.5.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Developments
  31. 6.6 Shanghai RAAS
  32. 6.6.1 Shanghai RAAS Company Information
  33. 6.6.2 Shanghai RAAS Business Overview
  34. 6.6.3 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  36. 6.6.5 Shanghai RAAS Recent Developments
  37. 6.7 Pacific Shuanglin Bio-pharmacy
  38. 6.7.1 Pacific Shuanglin Bio-pharmacy Company Information
  39. 6.7.2 Pacific Shuanglin Bio-pharmacy Business Overview
  40. 6.7.3 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  42. 6.7.5 Pacific Shuanglin Bio-pharmacy Recent Developments
  43. 6.8 Nanjing Pharmacare Co.,Ltd
  44. 6.8.1 Nanjing Pharmacare Co.,Ltd Company Information
  45. 6.8.2 Nanjing Pharmacare Co.,Ltd Business Overview
  46. 6.8.3 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  48. 6.8.5 Nanjing Pharmacare Co.,Ltd Recent Developments
  49. 6.9 Grifols, S.A.
  50. 6.9.1 Grifols, S.A. Company Information
  51. 6.9.2 Grifols, S.A. Business Overview
  52. 6.9.3 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  54. 6.9.5 Grifols, S.A. Recent Developments
  55. 6.10 Hualan Biological Engineering Inc.
  56. 6.10.1 Hualan Biological Engineering Inc. Company Information
  57. 6.10.2 Hualan Biological Engineering Inc. Business Overview
  58. 6.10.3 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  60. 6.10.5 Hualan Biological Engineering Inc. Recent Developments
  61. 6.11 Harbin Pacific Biopharmaceutical
  62. 6.11.1 Harbin Pacific Biopharmaceutical Company Information
  63. 6.11.2 Harbin Pacific Biopharmaceutical Business Overview
  64. 6.11.3 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  66. 6.11.5 Harbin Pacific Biopharmaceutical Recent Developments
  67. 6.12 Sinopharm Group Co., Ltd.
  68. 6.12.1 Sinopharm Group Co., Ltd. Company Information
  69. 6.12.2 Sinopharm Group Co., Ltd. Business Overview
  70. 6.12.3 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  72. 6.12.5 Sinopharm Group Co., Ltd. Recent Developments
  73. 6.13 Boya Bio-Pharmaceutical Group Co., Ltd.
  74. 6.13.1 Boya Bio-Pharmaceutical Group Co., Ltd. Company Information
  75. 6.13.2 Boya Bio-Pharmaceutical Group Co., Ltd. Business Overview
  76. 6.13.3 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  78. 6.13.5 Boya Bio-Pharmaceutical Group Co., Ltd. Recent Developments
  79. 6.14 Bayer AG
  80. 6.14.1 Bayer AG Company Information
  81. 6.14.2 Bayer AG Business Overview
  82. 6.14.3 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  84. 6.14.5 Bayer AG Recent Developments
  85. 6.15 Baxter International Inc.
  86. 6.15.1 Baxter International Inc. Company Information
  87. 6.15.2 Baxter International Inc. Business Overview
  88. 6.15.3 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  90. 6.15.5 Baxter International Inc. Recent Developments
  91. 6.16 Octapharma AG
  92. 6.16.1 Octapharma AG Company Information
  93. 6.16.2 Octapharma AG Business Overview
  94. 6.16.3 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  96. 6.16.5 Octapharma AG Recent Developments
  97. 6.17 CSL Behring
  98. 6.17.1 CSL Behring Company Information
  99. 6.17.2 CSL Behring Business Overview
  100. 6.17.3 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  102. 6.17.5 CSL Behring Recent Developments
  103. 6.18 ADMA Biologics, Inc.
  104. 6.18.1 ADMA Biologics, Inc. Company Information
  105. 6.18.2 ADMA Biologics, Inc. Business Overview
  106. 6.18.3 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolio
  108. 6.18.5 ADMA Biologics, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country
  2. 7.1.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
  4. 7.1.3 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032)
  5. 7.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country
  6. 7.2.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026)
  8. 7.2.3 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country
  2. 8.1.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
  4. 8.1.3 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country
  6. 8.2.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026)
  8. 8.2.3 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country
  2. 9.1.1 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country
  6. 9.2.1 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country
  2. 10.1.1 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
  4. 10.1.3 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032)
  5. 10.2 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country
  6. 10.2.1 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026)
  8. 10.2.3 South America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country
  2. 11.1.1 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country
  6. 11.2.1 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Value Chain Analysis
  2. 12.1.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Production Mode & Process
  7. 12.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors
  10. 12.2.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst